H.C. Wainwright lowered the firm’s price target on Iterum Therapeutics to $5 from $6 and keeps a Buy rating on the shares. The analyst cites equity dilution for the target drop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITRM:
- Iterum Therapeutics Reports Second Quarter 2024 Financial Results
- Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
- Iterum Therapeutics Announces Expiration and Results of Rights Offering
- Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem
- Iterum Therapeutics commences rights offering